WO/2015/151056 MAB-FCRN ASSAY||WO||08.10.2015|
||PCT/IB2015/052429||DR. REDDY'S LABORATORIES||SUBRAMANYAM, Satyam|
The present invention relates to methods and means for determining the relative binding activity of a therapeutic antibody based on the affinity of said antibody for a specific binding partner thereof. In particular, this invention relates to methods and means for use in FcRn binding assays wherein the competitive binding assay is performed between labelled Mab with F(ab')2 immune complex and unlabeled therapeutic X-Mab with the F(ab')2 immune complex to bind to the FcRn receptors. The assay as disclosed in tthe present invention picks up changes in Fc region like oxidation that impact FcRn binding. The assay is not influenced by minor differences in percent aggregates between therapeutic samples and hence be used for comparability assessment of one or more samples for binding to FcRn..
WO/2015/140700 CELL CULTURE PROCESS||WO||24.09.2015|
||PCT/IB2015/051930||DR. REDDY'S LABORATORIES LIMITED||THUDUPPATHY, Guru|
The invention discloses a cell culture process comprising culturing cells in the presence of betaine to obtain a glycoprotein with a glycoform composition comprising increased percentage of afucosylated glycans. Further, the invention 5 discloses a cell culture process comprising manganese, galactose and betaine for obtaining a glycoprotein with a glycoform composition comprising target values of mannosylated, galactosylated and afucosylated glycans.
WO/2015/132745 METHOD FOR DETECTION OF NEUTRALIZING ANTI-RITUXIMAB ANTIBODIES||WO||11.09.2015|
||PCT/IB2015/051602||DR. REDDY'S LABORATORIES LIMITED||VEMURI, Sireesha|
This invention is related to a method of detecting neutralizing activity of anti rituximab antibodies in a rheumatoid factor positive rheumatoid arthritis patient's sample, wherein the method retrieves anti-rituximab antibodies using an acidic buffer compatible with cell based CDC assay. In addition, the method employs use of 5 magnetic beads coupled rituximab for the retrieval of ARiA. The said method is able to measure the neutralizing anti-rituximab antibodies in presence of higher amounts of free rituximab and RF.
WO/2015/128795 PROCESS FOR MODIFYING GALACTOSYLATION AND G0F CONTENT OF A GLYCOPROTEIN COMPOSITION BY GLUTAMINE SUPPLEMENTATION||WO||03.09.2015|
||PCT/IB2015/051367||DR. REDDY'S LABORATORIES LIMITED||KADREPPA, Sreenath|
The invention relates to a cell culture process for decreasing the galactosylated content and/or increasing the G0F content of a glycoprotein. The process involves subjecting recombinant cells expressing the said glycoprotein to a temperature and pH shift and supplementing cell culture with glutamine.
WO/2015/125113 METHOD OF CULTURING HIGH CELL DENSITY PBMC'S||WO||27.08.2015|
||PCT/IB2015/051293||DR. REDDY'S LABORATORIES LIMITED||MEHTA, Gaurav Rajendraprasad|
The present invention relates to a method of attaining high cell density PBMCs that are viable for longer duration in culture. In particular the method involves culturing the cells in lymphocyte growth medium comprising recombinant human interleukin-2 and human serum to acquire cells with a density as high as 108 cells/ml. PBMCs thus obtained remains functionally viable for 25 to 30 days in culture and are also found enriched in NK cell content allowing it to be widely used as effector cells, particularly T-cell response assays.
WO/2015/123272 PARENTERAL COMPOSITIONS OF CELECOXIB||WO||20.08.2015|
||PCT/US2015/015379||DR. REDDY'S LABORATORIES LTD.||OKUMU, Franklin|
Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.
WO/2015/121784 METHOD FOR DETECTION OF ANTI-RITUXIMAB ANTIBODIES||WO||20.08.2015|
||PCT/IB2015/050949||DR. REDDY'S LABORATORIES LIMITED||LELLA, Ravi Kumar|
This invention is related to a method for detecting anti-rituximab antibodies in a RF positive plasma samples, wherein the method mitigated the interference of RF to a significant level using biotinylated F(ab)2 fragments of rituximab as detecting agent. The method also used a pre-treatment step with acidic buffer containing glycine, prior to subjecting the samples for detection of anti-rituximab antibodies.
WO/2015/107444 IN-VITRO ASSAY FOR THE ASSESSMENT OF POST TRANSLATIONALLY MODIFIED PROTEIN ISOFORMS||WO||23.07.2015|
||PCT/IB2015/050212||DR.REDDYS LABORATORIES LIMITED||MEDISETTY, Rajesh|
The present invention discloses an in-vitro bioassay for distinguishing post translationally modified isoforms of a protein. In particular, the present invention discloses an in-vitro method for distinguishing post translationally modified isoforms of an antibody by C1q based ELISA involving a metal ion chelator.
WO/2015/059679 IMPROVED PROCESS FOR THE PREPARATION OF ELIGLUSTAT||WO||30.04.2015|
||PCT/IB2014/065631||DR. REDDY'S LABORATORIES LIMITED||JAVED, Iqbal|
The present invention provides an improved process for the preparation of eliglustat to salts thereof. Present invention also provides a crystalline eliglustat free base form R1.
WO/2015/044876 MOLECULAR WEIGHT MARKERS FOR PROTECTED POLYPEPTIDES||WO||02.04.2015|
||PCT/IB2014/064797||DR. REDDY'S LABORATORIES LIMITED||KATKAM, Srinivas|
The present invention provides trifluoroacetyl copolymers useful as standard molecular weight markers in the intermediary stage for obtaining glatiramer acetate having desired average molecular weight. The present invention further provides a process for determining the average molecular weight of glatiramer acetate or other copolymers using molecular weight markers of protected polypeptides.